 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | YTS105 / BriSTAR Immunotech
Journal: Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 Sys-tem versus the da Vinci System: a multicenter prospective randomized controlled trial. (Pubmed Central) - Sep 3, 2024
The KD-SR-01 system is safe and effective for RARNU compared to the DV Si or Xi system. Further randomized controlled studies with larger sample sizes and longer durations are required.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, YTS105 / Peking University, BriSTAR Immunotech
Retrospective data, Journal, Checkpoint inhibition: Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study. (Pubmed Central) - Dec 13, 2023
The median time from ICI initiation to colitis onset was 105 days...Twenty-three (92%) patients received steroids, and 3 (12%) added infliximab (IFX)...ICI rechallenge can achieve benefit, but permanently discontinuing ICIs is needed if colitis recurs. Future large-scale prospective studies are required for more accurate assessments and validation.
- | YTS105 / Peking University, BriSTAR Immunotech
Journal: Muricauda meishanensis sp. nov., a facultative anaerobic bacterium belonging to the family Flavobacteriaceae isolated from marine sediment in the East China Sea. (Pubmed Central) - Sep 26, 2023
The 16S rRNA gene sequence analyses revealed that strain NBU2970 represents a novel species with the genus Muricauda, sharing highest sequence identities with Muricauda beolgyonensis BB-My12 (96.1?%), Muricauda alvinocaridis SCR12 (96.0?%), Muricauda taeanensis 105 (96.0?%) and Muricauda ruestringensis B1 (95.6?%)...is proposed. The type strain is NBU2970 (=KCTC 82915=MCCC 1K06394).
- ABSK021 / Abbisko
PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE () - Sep 9, 2022 - Abstract #CTOS2022CTOS_424;
P1
ABSK021 has demonstrated significant antitumor activity and favourable safety profile with no apparent hepatotoxicity associated with CSF-1R inhibitors. This is the first result of an oral CSF-1R inhibitor with encouraging preliminary efficacy and safety results in Chinese advanced TGCT patients, which supports the further evaluation of ABSK021 as a promising treatment option for this disease.
- | YTS105 / BriSTAR Immunotech
New P1 trial, Metastases: MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 25, 2022
P1, N=12, Not yet recruiting, Sponsor: Peking University